

Appendix 2 - Shared Care Summary

Drug	Development / review					APC		EPACT Patients	Primary care monitoring requirements				
	Reference	Version	Source	Date	Review	Notes	Approved		Date	Monthly	3 monthly	6 monthly	Annual
Antipsychotics	LMMG 01	1.1	LMMG	Mar-18	Mar-21		Yes	Jun-18	2901				Weight, Waist circumference, Pulse and blood pressure, Fasting blood glucose or HbA1c, blood lipid and prolactin levels, Side effects to treatment, emergence of movement disorders, and overall physical health
Apomorphine	LMMG 02	1.0	LMMG	Jan-17		LCT SCG	Yes	Jan-17	9			Haemoglobin and reticulocyte count	
Azathioprine	LMMG 03	2.1	LMMG	Sep-18	Sep-20	Aza + merc	Yes	Sep-17	392		FBC, LFT, albumin, creatinine/GFR, ESR/CRP		
Ciclosporin	LMMG 04	2.1	LMMG	Sep-18	Sep-20		Yes	Sep-17	57	FBC, LFT, K+, creatinine/GFR, albumin, BP, glucose			
ADHD - adults & children	LMMG 05	1.0	LMMG	Oct-18	Oct-21		Yes	Oct-18	633				All other drugs Cardiac function and BP Height, weight and appetite New or worsening psychiatric symptoms Onset or exacerbation of motor and verbal tics Sleep Pattern (e.g. sleep diary) Sexual dysfunction (atomoxetine only) LFT, cardiac evaluation, BMI
ADHD - adults & children (GUANFACINE)	LMMG 05	1.0	LMMG	Oct-18	Oct-21		Yes	Oct-18	7		Guanfacine only Cardiac function and BP Height, weight and appetite Somnolence / Sedation Sleep Pattern (e.g. sleep diary) LFT, cardiac evaluation, BMI		
Denosumab for osteoporosis	LMMG 06	3.0	LMMG	Apr-18	Apr-21		Yes	Apr-18	43				Creatinine/GFR, Ca and vit D, assess for side effects, oral hygiene, falls risk assessment
Leflunomide	LMMG 07	2.1	LMMG	Sep-18	Sep-20		Yes	Sep-17	144		FBC, creatinine/GFR, LFT, albumin, weight, ESR or CRP, BP		
Lithium	LMMG 08	1.1	LMMG	Apr-16	Apr-19		Yes	Jul-16	308		Serum lithium	U&Es, TFT,	Blood glucose, BP, lipid profile, weight
Mercaptopurine	LMMG 09	2.1	LMMG	Sep-18	Sep-20	Mercap +	Yes	Sep-17	29		FBC, LFT, albumin, creatinine/GFR, ESR/CRP		
Methotrexate	LMMG 10	2.1	LMMG	Sep-18	Sep-20		Yes	Sep-17	1337		FBC, creatinine/GFR, LFT, albumin, ESR or CRP, BP, P3NP		
Mycophenolate (unlicensed)	LMMG 11	2.1	LMMG	Sep-18	Sep-20		Yes	Jul-17	55	FBC, creatinine/GFR, LFT, albumin			
Penicillamine	LMMG 12	2.1	LMMG	Sep-18	Oct-20		Yes	Sep-17	3	FBC, U&Es, creatinine/GFR, urinalysis	ESR/CRP		
Riluzole	LMMG 13	1.1	LMMG	Dec-15	Dec-18		Yes	Mar-16	8		FBC, U&Es, LFT, ALT in first 12 months		FBC, U&Es, LFT, ALT after first 12 months
Sodium aurothiomalate	LMMG 14	2.1	LMMG	Sep-18	Sep-20		Yes	Sep-17	3	FBC, Urinalysis, ESR/CRP			
Mesalazine									749		FBC, LFT, U&Es, creatinine/GFR, ESR/CRP		
Sulfasalazine	LMMG 15	2.1	LMMG	Sep-18	Oct-20		Yes	Sep-17	340		FBC, LFT, U&Es, creatinine/GFR, ESR/CRP		
Testosterone	LMMG 16	1.0	LMMG	Nov-18	Nov-21		Yes	Sep-18	98		In first 12 months Haematocrit, serum oestradiol, haemoglobin, LFT, lipids, prostate and PSA, testosterone		After first 12 months Haematocrit, serum oestradiol, haemoglobin, LFT, lipids, prostate and PSA, testosterone
Enoxaparin	UHMB 07	4.1	UHMB/NCH	May-15	Mar-19		Yes	May-15	176	(short term)			
Dapsone	UHMB 08	1.1	UHMB/NCH	May-16	Oct-18		Yes	May-16	17		FBC, LFT		
Hydroxycarbamide	UHMB 11	2.1	UHMB/NCH	Dec-16	Dec-19		Yes	Dec-16	81		FBC		
TOTALS									7,390				